Pharmacy Daily | GBMA’s board positions

THE peak body for affordable medicines has welcomed two new board members at a pivotal time for the health budget and medicine policy reforms.

The Generic and Biosimilar Medicines Association's (GBMA) Independent Chair, Prof Jane Halton AO PSM, and CEO, Marnie Peterson, have welcomed Clint Holland and Hayley Tamborini, noting that the board additions came at a time when the industry is experiencing significant policy shift, alongside the changing landscape of medicines.

Halton said the two board members have joined at a dynamic time in medicine policy, and as patients and their families face the rising cost of living.

"The mission critical aim of the GBMA board, is shared with the Government and that is to provide fiscal relief to a stretched health budget and ensure all Australians have access to the affordable medicines they need, when they need them," Halton said.

Holland is the new Country Head of Sandoz ANZ and Tamborini is the Executive General Manager, Pharmaceuticals at Arrotex.

A former pharmacist, Tamborini leads the strategic direction of the Arrotex prescription business, specialty brands portfolio and biologics division.

Recently, this has expanded to include a new Medical Division of 50 sales professionals collaborating with prescribers, in both primary and secondary care settings.

Tamborini said she was committed to working with her GBMA board colleagues to ensure the focus continues to remain on policies that support the accelerated and continued uptake of generics and biosimilars.

"We need to drive further investment in the development of generic and biosimilar medicines.

"Timely access to medicines is critically important to the health of all Australians," said Tamborini.